NDRA (ENDRA Life Sciences) קצב צמיחת רווח למניה בשנה הנוכחית

ENDRA Life Sciences possesses a strong team of researchers, yet product time-to-market has been prolonged. The primary risks are potential regulatory rejections and capital shortages. The success of TAEUS systems depends on insurance payouts rather than economics. The annual earnings per share growth indicator reflects current dynamics, where the 0.00 mark serves as a key metric.

To minimize capital freeze risks, investors must filter issuers based on net earnings per share dynamics. This metric measures the percentage deviation of current EPS from the previous year's value, reflecting real-time income generation efficiency. When analyzing the annual earnings per share growth vector on GURU.Markets, it is essential to correlate it with the commercialization of the TAEUS platform's AI algorithms for hepatic steatosis diagnostics at ENDRA Life Sciences (NDRA).